Cytel and GSK have entered into a three-year strategic agreement for advancing clinical trial designs with the Solara strategy platform.
The partnership will offer critical input for the platform’s future development.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe first-to-market clinical trial strategy platform is developed for simulation-guided study design and selection.
Clinical development teams can quickly generate thousands of trial models using Solara.
These models are used for pressure-testing against many trial uncertainties, including treatment effect and enrolment rate.
The high-speed processing capability of the platform can simulate many modelled events that may be observed during the execution of clinical trials.
The visualisations of Solara help in reviewing the results easily and offers the ability to quantify scientific and business trade-offs.
Solara combines Cytel’s algorithms with massive Cloud compute power for overcoming constraints in planning and designing trials.
Cytel chief product officer and Software general manager Scott Gaines said: “Solara was launched to facilitate a more quantitative, robust, and collaborative approach to clinical trial design, with the goal of accelerating the development of new medicines.
“Seeing Solara used by GSK to optimise design selection across multiple projects is an important realisation of this vision.”
The company stated that its platform can enable GSK to efficiently align on trial goals, navigate uncertainties, and generate pressure-tested designs that help lessen costs and improve speed to market.
GSK Statistics and Data Sciences Innovation Hub vice-president Nicky Best said: “Our experience from the pilot studies we conducted last year has shown that Solara is a powerful and innovative platform, with an exciting vision.
“As Solara is deployed more broadly at GSK, we are eager to see the potential of how it could help to super-charge our existing quantitative decision-making framework to gain further efficiencies in our clinical trial design process, and to create the productive, evidence-based conversations that we want our teams and governance boards to be engaging in.”
